Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Belvidere-based Edible Garden is bringing something new to the table. After a successful pilot production, the hydroponic ...

The research uncovers key genetic mutations that affect cancer treatment responses and develops a predictive tool for ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

A study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence ...